Galderma Group (PY3) Stock Overview
Operates as a dermatology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PY3 from our risk checks.
PY3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Galderma Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 121.00 |
| 52 Week High | CHF 124.00 |
| 52 Week Low | CHF 100.00 |
| Beta | 0 |
| 1 Month Change | 11.01% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 14.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| PY3 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.7% | -3.6% | -1.2% |
| 1Y | n/a | -23.9% | 15.5% |
Return vs Industry: Insufficient data to determine how PY3 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PY3 performed against the German Market.
Price Volatility
| PY3 volatility | |
|---|---|
| PY3 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: PY3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine PY3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 6,545 | Flemming Ornskov | www.galderma.com |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.
Galderma Group AG Fundamentals Summary
| PY3 fundamental statistics | |
|---|---|
| Market cap | €28.24b |
| Earnings (TTM) | €200.53m |
| Revenue (TTM) | €3.85b |
Is PY3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PY3 income statement (TTM) | |
|---|---|
| Revenue | US$4.44b |
| Cost of Revenue | US$1.36b |
| Gross Profit | US$3.09b |
| Other Expenses | US$2.85b |
| Earnings | US$231.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 24, 2025
| Earnings per share (EPS) | 0.97 |
| Gross Margin | 69.48% |
| Net Profit Margin | 5.20% |
| Debt/Equity Ratio | 33.9% |
How did PY3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/23 11:10 |
| End of Day Share Price | 2025/06/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galderma Group AG is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fulvio Cazzol | Berenberg |
| Bethan Davies | Berenberg |
| Hugo Solvet | BNP Paribas Exane |